Maximal response to treatment with VEN, LEN, and rituximab in R/R MCL, in total, and according to exposure to a BTKi (ibrutinib)
| . | Total (N = 59) . | BTKi exposure (n = 15) . |
|---|---|---|
| ORR | 37 (63%; 95% CI, 50-74) | 6 (40%; 95% CI, 20-64) |
| Complete remission | 29 (49%; 95% CI, 37-62) | 4 (27%; 95% CI, 11-50) |
| Partial remission | 8 (14%; 95% CI, 7-25) | 2 (13%; 95% CI, 3-38) |
| Stable disease | 5 (8%; 95% CI, 3-18) | 2 (13%; 95% CI, 3-38) |
| Progressive disease/stopped early | 17 (29%; 95% CI, 19-41) | 7 (47%; 95% CI, 25-70) |
| . | Total (N = 59) . | BTKi exposure (n = 15) . |
|---|---|---|
| ORR | 37 (63%; 95% CI, 50-74) | 6 (40%; 95% CI, 20-64) |
| Complete remission | 29 (49%; 95% CI, 37-62) | 4 (27%; 95% CI, 11-50) |
| Partial remission | 8 (14%; 95% CI, 7-25) | 2 (13%; 95% CI, 3-38) |
| Stable disease | 5 (8%; 95% CI, 3-18) | 2 (13%; 95% CI, 3-38) |
| Progressive disease/stopped early | 17 (29%; 95% CI, 19-41) | 7 (47%; 95% CI, 25-70) |